Vonoprazan for Helicobacter pylori eradication and for treating erosive esophagitis, non-erosive gastroesophageal reflux disease (NERD), and gastroesophageal reflux disease (GERD).
Takeda Pharmaceutical
Posted inInfections, New Drugs, Regulatory
Livtencity: New Drug Against Post-Transplant Cytomegalovirus Infection
Maribavir will suppress cytomegalovirus when ganciclovir, valganciclovir, cidofovir, or foscarnet do not work.
Posted inMergers & Acquisitions, Oncology
Takeda Bets on Promising Gamma Delta T-cell Immunotherapy
UK-based GammaDelta Therapeutics has developed a pipeline of novel allogeneic cell therapies.
Posted inAutoimmune Diseases, New Drugs, Regulatory
Zeposia: New Drug for Ulcerative Colitis
Oral ozanimod will provide clinical remission of ulcerative colitis for a third of patients.
Posted inPharma & Biotech
Halozyme: Elegant Transformation of Drugs From Intravenous to Subcutaneous
Easy and quick administration of biological drugs. All for the convenience of patient care.
Posted inDrug Safety, Metabolism, Regulatory
Febuxostat in Treatment of Gout: Walk With Death
A popular antigout drug Uloric carries increased risks of death.
Posted inOncology, Research
Not All Cancer Drugs Are Equally Useful
Cheating out of ignorance, or Sleight of hand and no fraud. How pharmaceutical companies scam clinical trials.
